


1fw



ATTORNEY DOCKET NO.: 0492611-0506 (MIT9926)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chen et al. Examiner:
Serial No.: 10/674,159 Art Unit: 1635
Filing Date: September 29, 2003
Title: Influenza Therapeutic

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (6 pages);
2. Information Disclosure Statement (5 pages);
3. Transmittal Letter (1 page)
4. Cited Art (98); and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Monica R. Gerber

Monica R. Gerber, M.D., Ph.D.
Reg. No. 46,724

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000


Dated: Dec 20, 2004
3781487

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12-20-04 Sandra Saccoccia
Date Signature
Sandra Saccoccia

Typed or Printed Name of person signing certificate



ATTORNEY DOCKET: 0492611-0506 (MIT9926)
THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chen, et al.
Serial No: 10/674,159
Filed: September 29, 2003
For: "Influenza Therapeutic"

Art Unit:
Examiner: 1635

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☒ [X] An *original* Information Disclosure Statement; or
☐ [] A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12-20-04

Date

Sandra Saccoccia

Signature

Sandra Saccoccia

Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
 - ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
 - ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual

designated in § 1.56(c) more than three months prior to the filing of
the information disclosure statement; or

☐ Includes herewith the fee set forth in § 1.17(p),

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under
§ 1.113, a notice of allowance under § 1.311, or an action that otherwise closes
prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure
statement was first cited in any communication from a foreign
patent office in a counterpart foreign application not more than
three months prior to the filing of the information disclosure
statement; or

☐ That no item of information contained in the information
disclosure statement was cited in a communication from a foreign
patent office in a counterpart foreign application, and, to the
knowledge of the person signing the certification after making
reasonable inquiry, no item of information contained in the
information disclosure statement was known to any individual
designated in § 1.56(c) more than three months prior to the filing of
the information disclosure statement; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Includes one or more translations of a non-English citation; or
- ☐ Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: Dec. 20, 2004


Monica R. Gerber, M.D., Ph.D.
Reg. No. 46,724

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 0492611-0506 (MIT 9926)		In re Application No. 10/674,159	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Chen, et al.			
				Filing Date: September 29, 2003		Group:	
U.S. PATENT DOCUMENTS							
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass		
U.S. PATENT APPLICATIONS							
Examiner's Initials:	Publication Number:	Applicant:	Publication Date:	Group:	Art Unit:		
	2002/0127620	Witman et al.	September 12, 2002				
	2002/0061861	Herweijer et al.	May 23, 2002				
	2002/0081736	Conroy et al.	June 27, 2002				
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document No.	Country	Date	Translation			
				Yes	No		
	WO 01/75164	PCT	11 October 2001				
OTHER DOCUMENTS							
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Ahn, et al., "Biodegradable Poly(Ethylenimine) for Plasmid DNA Delivery", <i>J. Control. Release</i> , 80 : 273-282, 2002.						
	Allinquant, et al., "Downregulation of Amyloid Precursor Protein Inhibits Neurite Outgrowth in Vitro", <i>J. Cell. Biol.</i> 128 : 919-927, 1995.						
	Amarzguioui, et al., "Tolerance for Mutations and Chemical Modifications in a siRNA", <i>Nuc. Acids. Res.</i> 31 (2): 589-595, 2003.						
	Anderson, et al., "Semi-Automated Synthesis and Screening of a Large Library of Degradable Cationic Polymers for Gene Delivery", <i>Angew Chem. Int. Ed. Engl.</i> 42 : 3153-3158, 2003.						
	Astafieva, et al., "Enhancement of the Polycation-Mediated DNA Uptake and Cell Transfection with Pluronic P85 Block Copolymer", <i>FESB Letter</i> , 389 : 278-280, 1996.						
	Avery, et al., "Surface Properties in Relation to Atelectasis and Hyaline Membrane Disease", <i>Am. J. Dis. Child.</i> , 97 : 517-523, 1959.						
	Baker, et al., Novel Mechanims for Antisense-Mediated Regulation of Gene Expression", <i>Biochimica et Biophysica Acta</i> , 1489 : 3-18, 1999.						
	Baughman, et al., "Tissue Distribution and Abundance of Human FKBP51, and FK506-Binding Protein That Can Mediate Calcineurin Inhibition", <i>Biochemical and Biophysical Research Communications</i> , 232 : 437-443, 1997.						
	Baulcombe, D., "RNA Silencing", <i>Curr. Biol.</i> 12 : R82-R84, 2002.						

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		U.S. Department of Commerce Patent and Trademark Office Atty. Docket: 0492611-0506 (MIT 9926) Applicant: Chen, et al. Filing Date: September 29, 2003		In re Application No. 10/674,159		
	Beaton, et al., "Transcription Antitermination During Influenza Viral Template RNA Synthesis Requires the Nucleocapsid Protein and the Absence of a 5' Capped End", <i>Proc. Natl Acad. Sci. USA</i> , 83 : 6282-6286, 1986.					
	Benns, et al., "Optimization of Factors Influencing the Transfection Efficiency of Folate-PEG-Folate-Graft Polyethyleneimine", <i>J. Cont. Release</i> , 79 : 255-269, 2002.					
	Benns, et al., "pH-Sensitive Cationic Polymer Gene Delivery Vehicle: N-Ac-Poly(L-Histidine)-Graft-Poly(L-Lysine) Comb Shaped Polymer", <i>Bioconj. Chem.</i> 11 : 637-645, 2000.					
	Bernstein, et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference", <i>Nature</i> , 409 : 363-366, 2001.					
	Berry, et al., "Neonatology in the 1990's: Surfactant Replacement Therapy Becomes a Reality", <i>Clin. Pediatr.</i> 30 (3): 167-170, 1991.					
	Bitko, et al., "Phenotype Silencing of Cytoplasmic Genes Using Sequence-Specific Double-Stranded Short Interfering RNA and its Application in the Reverse Genetic of Wild Type Negative-Strand RNA Viruses", <i>BMC Microbiol.</i> 1 : 34-43, 2001.					
	Bloom, et al., "Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome", <i>Pediatrics</i> , 100 : 31-38, 1997.					
	Boehnke, et al., "A Look at Linkage Disequilibrium", <i>Nature Genetics</i> , 25 : 246-247, 2000.					
	Boussif, et al., "A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in Vivo: Polyethylenimine", <i>Proc. Natl. Acad. Sci. USA</i> , 92 : 7297-7301, 1995.					
	Boute, et al., "The Use of Resonance Energy Transfer in High-Throughput Screening: BRET Versus FRET", <i>Trends in Pharmacological Sciences</i> , 23 (8): 351-354, 2002.					
	Braasch, et al., "RNA Interference in Mammalian Cells by Chemically Modified RNA", <i>Biochemistry</i> , 42 : 7967-7975, 2003.					
	Brantl, S., "Antisense-RNA Regulation and RNA Interference", <i>Biochem. Biophys. Acta</i> , 1575 : 15-25, 2002.					
	Brissault, et al., "Synthesis of Linear Polyethylenimine Derivatives for DNA Transfection" <i>Bioconj Chem.</i> , 14 (3): 581-587, 2003.					
	Brummelkamp, et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells", <i>Science</i> , 296 : 550-553, 2002.					
	Brzustowicz, et al., "Location of a Major Susceptibility Locus for Familial Schizophrenia on Chromosome 1q21-q22", <i>Science</i> , 288 : 678-682, 2000.					
	Camp, et al., "Genomewide Multipoint Linkage Analysis of Seven Extended Palauan Pedigrees with Schizophrenia, by a Markov-Chain Monte Carlo Method", <i>Am. J. Hum. Genet.</i> 69 : 1278-1289, 2001.					
	Caplen, et al., "dsRNA-Mediated Gene Silencing in Cultured Drosophila Cells: A Tissue Culture Model for the Analysis of RAN Interference", <i>Gene</i> , 252 : 95-105, 2000.					
	Castle, S.C., "Clinical Relevants of Age-Related Immune Dysfunction", <i>Clin. Infect. Dis.</i> , 31 :					

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0492611-0506 (MIT 9926)	In re Application No. 10/674,159
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Chen, et al.	
		Filing Date: September 29, 2003	Group:
	578-585, 2000.		
	Chi, et al., "Genomewide View of Gene Silencing by Small Interfering RNAs", <i>Proc. Natl. Acad. Sci. USA</i> , 100 : 6343-6346, 2003.		
	Chiu, et al., "siRNA Function in RNAi: A Chemical Modification Analysis", <i>RNA</i> , 9 (9): 1034-1048, 2003.		
	Claas, et al., "Human Influenza A H5N1 Virus Related to a Highly Pathogenic Avian Influenza Virus", <i>Lancet</i> , 351 : 472-477, 1998.		
	Clayton, D., "A Generalization of the Transmission/Disequilibrium Test for Uncertain-Haplotype Transmission", <i>Am. J. Hum. Genet.</i> 65 : 1170-1177, 1999.		
	Cox, et al., "Influenza", <i>Lancet</i> , 354 : 1277-1282, 1999.		
	Craddock, et al., "Chromosome Workshop: Chromosomes 11, 14, and 15", <i>American Journal of Medical Genetics (Neuropsychiatric Genetics)</i> , 88 : 244-254, 1999.		
	Crowe, et al., "Report of the Chromosome 5 Workshop of the Sixth World Congress on Psychiatric Genetics", <i>American Journal of Medical Genetics (Neuropsychiatric Genetics)</i> , 88 : 229-232, 1999.		
	Czauderna, et al., "Structural Variations and Stabilising Modifications of Synthetic siRNAs in Mammalian Cells", <i>Nucleic Acids Research</i> , 31 (11): 2705-2716, 2003.		
	Densmore, et al., "Aerosol Delivery of Robust Polyethyleneimine-DNA Complexes for Gene Therapy and Genetic Immunization", <i>Mol. Therapy</i> , 1 : 180-188, 1999.		
	Derossi, et al., "Trojan-Peptides: The Penetratin System for Intracellular Delivery" <i>Trends Cell Biol.</i> 8 : 84-87, 1998.		
	Diaz, et al., "Homozygous Deletion of the α - and β_1 - Interferon Genes in Human Leukemia and Derived Cell Lines", <i>Proc. Natl. Acad. Sci. USA</i> , 85 : 5259-5263, 1988.		
	Diaz, et al., "Structure of the Human Type-1 Interferon Gene Cluster Determined from a YAC Clone Contig", <i>Genomics</i> , 22 : 540-552, 1994.		
	Edwards, et al., "Large Porous Particles for Pulmonary Drug Delivery", <i>Science</i> , 276 : 1868-1871, 1997.		
	Elbashir, et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells", <i>Nature</i> , 411 : 494-498, 2001.		
	Elbashir, et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in Drosophila Melanogaster Embryo Lysate", <i>EMBO J</i> , 20 : 6877-6888, 2001.		
	Fawell, et al., "Tat-Mediated Delivery of Heterologous Proteins into Cells", <i>Proc. Natl. Acad. Sci. USA</i> , 91 : 664-668, 1994.		
	Fire, et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans", <i>Nature</i> , 391 : 806-811, 1998.		
	Futaki, et al., "Arginine-Rich Peptides. An Abundant Source of Membrane-Permeable Peptides Having Potential as Carriers for Intracellular Protein Delivery", <i>J. Biol. Chem.</i> 276 :		

Form PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0492611-0506 (MIT 9926)	In re Application No. 10/674,159
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Chen, et al.	
		Filing Date: September 29, 2003	Group:
	5836-5840, 2001.		
	Ge, et al., "RNA Interference of Influenza Virus Production by Directly Targeting mRNA for Degradation and Indirectly Inhibiting all Viral RNA Transcription", <i>Proc. Natl Acad. Sci. USA</i> , 100 : 2718-2723, 2003.		
	Gil, et al., "Induction of Apoptosis by the dsRNA-Dependent Protein Kinase (PKR): Mechanism of Action", <i>Apoptosis</i> , 5 : 107-114, 2000.		
	Gitlin, et al., "Short Interfering RNA Confers Intracellular Antiviral Immunity in Human Cells", <i>Nature</i> , 418 : 430-434, 2002.		
	Gratton, et al., "Cell-Permeable Peptides Improve Cellular Uptake and Therapeutic Gene Delivery of Replication-Deficient Viruses and In Vivo", <i>Nat. Med.</i> , 9 (3): 357-362, 2003.		
	Green, et al., "Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat Trans-Activator Protein", <i>Cell</i> , 55 : 1179-1188, 1988.		
	Han, et al., "Development of Biomaterials for Gene Therapy", <i>Mol. Therapy</i> , 2 : 302-317, 2000.		
	Griesenbach, et al., "Comparison Between Intratracheal and Intravenous Administration of Liposome-DNA Complexes for Cystic Fibrosis Lung Gene Therapy", <i>Gene Ther.</i> 5 : 181-188, 1998.		
	Hall, et al., "Importance of Hydrophobic Apoproteins as Constituents of Clinical Exogenous Surfactants", <i>Am. Rev Respir Dis.</i> 145 : 24-30, 1992.		
	Hallman, et al., "Natural Surfactant Substitution In Respiratory Distress Syndrome", <i>J. Perinat Med.</i> 15 : 463-468, 1987.		
	Hansen, et al., "Re-examination and Further Development of a Precise and Rapid Dye Method for Measuring Cell Growth/Cell Kill", <i>J. Immunol. Methods</i> , 119 : 203-210, 1989.		
	Holen, et al., "Positional Effects of Short Interfering RNAs Targeting the Human Coagulation Trigger Tissue Factor", <i>Nucleic Acids Res.</i> 30 : 1757-1766, 2002.		
	Jeong, et al., "Poly(L-Lysine)-g-Poly(D,L-Lactic-Co-Glycolic Acid) Micelles for Low Cytotoxic Biodegradable Gene Delivery Carriers", <i>J. Control Release</i> , 82 (1): 159-166, 2002.		
	Jobe, A, "Surfactant Treatment for Respiratory Distress Syndrome", <i>Respir Care</i> , 31 (6): 467-476, 1986.		
	Joliot, et al., "Antennapedia Homeobox Peptide Regulates Neural Morphogenesis", <i>Proc. Natl. Acad. Sci. USA</i> , 88 : 1864-1868, 1991.		
	Kichler, et al., "Histidine-Rich Amphipathic Peptide Antibiotics Promote Efficient Delivery of DNA into Mammalian Cells" <i>Pro Natl Acad Sci USA</i> , 100 (4): 1564-1568, 2003.		
	Lavik, et al., "A Simple Synthetic Route to the Formation of a Block Copolymer of Poly(lactic-co-glycolic acid) and Polylysine for the Fabrication of Functionalized, Degradable Structures for Biomedical Applications", <i>J. Biomed Mater Res (Appl Biomater)</i> , 58 : 291-294, 2001.		

Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0492611-0506 (MIT 9926)	In re Application No. 10/674,159
		Applicant: Chen, et al.	
		Filing Date: September 29, 2003	Group:
	Lee, et al., "Expression of Small Interfering RNAs Targeted Against HIV-1 Rev Transcripts in Human Cells", <i>Nature Biotechnology</i> , 19 : 500-505, 2002.		
	Lewis, et al., "Efficient Delivery of siRNA for Inhibition of Gene Expression in Postnatal Mice", <i>Nat. Genet.</i> 32 : 107-108, 2002.		
	Lois, et al., "Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vector" <i>Science</i> , 295 : 868-872, 2002.		
	McCaffrey, et al., "RNA Inteference in Adult Mice", <i>Nature</i> , 418 : 38-39, 2002.		
	McCaffrey, et al., "Inhibition of Hepatitis B Virus in Mice by RNA Interference", <i>Nat. Biotechnol.</i> 21 : 639-644, 2003.		
	McKenzie, et al., "A Potent New Class of Reductively Activated Peptide Gene Delivery Agents", <i>J. Biol. Chem.</i> , 275 (14): 9970-9977, 2000.		
	Miyagishi, et al., "U6 Promoter-Driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells", <i>Nature Biotechnology</i> , 19 : 497-500, 2002.		
	Paddison, et al., "Short Hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells", <i>Genes Dev.</i> 16 : 948-958, 2002.		
	Panyam, et al., "Rapid Endolysosomal Escape Poly(DL-Lactide-Co-Glycolide) Nanoparticles: Implications for Drug and Gene Delivery", <i>FASEB J.</i> , 16 : 1217-1226, 2002.		
	Park, et al., "Synthesis of Sulfhydryl Cross-Linking Poly(Ethylene Glycol Peptides and Glycopeptides as Carriers for Gene Delivery", <i>Bioconjugate Chem.</i> , 13 : 232-239, 2000.		
	Paul, et al., "Effective Expression of Small Intefering RNA in Human Cells", <i>Nature Biotechnology</i> , 29 : 505-508, 2002.		
	Putnam, et al., "Polymer-Based Gene Delivery with Low Cytotoxicity by a Unique Balance of Side-Chain Termini", <i>Proc. Natl. Acad. Sci. USA</i> , 98 : 1200-1205, 2001.		
	Putnam, et al., "Polyhistidine-PEG: DNA Nanocomposites for Gene Delivery", <i>Biomaterials</i> , 24 : 4425-4433, 2003.		
	Robinson, et al., "A Lentivirus-Based System to Functionally Silence Genes in Primary Mammalian Cells, Stem Cells and Transgenic Mice by RNA Inteference", <i>Nat. Genet.</i> , 33 : 401-406, 2003.		
	Semizarov, et al., "Specificity of Short Interfering RNA Determined Through Gene Expression Signatures", <i>Proc. Natl. Acad. Sci. USA</i> , 100 : 6347-6352, 2003.		
	Sharp, P.A., "RNA Interference", <i>Genes Dev.</i> 15 : 485-490, 2001.		
	Shen, et al., "Gene Expression and Mucosal Immune Responses After Vaginal DNA Immunization in Mice Using a Controlled Delivery Matrix", <i>Journal of Controlled Release</i> , 86 : 339-348, 2003.		
	Simeoni, et al., "Insight into the Mechanism of the Peptide-Based Gene Delivery System MPG: Implication for Delivery of siRNA into Mammalian Cells", <i>Nucleic Acids Res.</i> 31 :		

Form PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 0492611-0506 (MIT 9926)	In re Application No. 10/674,159
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				Applicant: Chen, et al.	
				Filing Date: September 29, 2003	Group:
	2717-2724, 2003.				
	Sobin, et al., "Early Non-Psychotic Deviant Behavior in Schizophrenia: a Possible Endophenotypic Marker for Genetic Studies", <i>Psychiatry Research</i> , 101 : 101-113, 2001.				
	Thomas, et al., "A Non-Viral Gene Therapy: Polycation-Mediated DNA Delivery", <i>Appl. Microbiol. Biotechnol.</i> 62 : 27-34, 2003.				
	Tiyaboonchai, et al., "Formulation and Characterization of DNA-Polyethylenimine-Dextran Sulfate Nanoparticles", <i>Eur. J. Pharm. Sci.</i> 19 : 191-202, 2003.				
	Tuschl, Thomas, "Expanding Small RNA Interference", <i>Nature Biotechnology</i> , 20 : 446-448, 2002.				
	Weiss, et al., "Delivery of Gene Transfer Vectors to Lung: Obstacles and the Role of Adjunct Techniques for Airway Administration", <i>Molecular Therapy</i> , 6 (2): 148-152, 2002.				
	Xia, et al., "siRNA-Mediated Gene Silencing in Vitro and in Vivo", <i>Nat. Biotechnol.</i> 20 : 1006-1010, 2002.				
	Yang, et al., "Evidence that Processed Small dsRNAs May Mediate Sequence-Specific mRNA Degradation During RNAi in Drosophila Embryos", <i>Curr. Biol.</i> 10 : 1191-1200, 2000.				
	Yang, et al., "Hydrodynamic Injection of Viral DNA: A Mouse Model of Acute Hepatitis B Virus Infection", <i>Proc. Natl. Acad. Sci.</i> , 99 (21): 13825-13830, 2000.				
	Yuen, et al., "Clinical Features and Rapid Viral Diagnosis of Human Disease Associated with Avian Influenza A H5N1 Virus", <i>Lancet</i> , 351 : 467-471, 1998.				
	Zhang, et al., "The In Vivo Use of Chloroquine to Promote Non-Viral Gene Delivery to the Liver via the Portal Vein and Bile Duct", <i>J. Gene Med.</i> , 5 : 209-218, 2003.				
	Zhang, et al., "Long-Term Expression of Human Alpha1-Antitrypsin Gene in Mouse Liver Achieved by Intravenous Administration of Plasmid DNA Using a Hydrodynamics-Based Procedure", <i>Gene Ther.</i> , 7 : 1344-1349, 2000.				
	International Search Report issued for corresponding PCT application PCT/US03/30508.				
EXAMINER				DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					